|
| Press Releases |
|
 |
|
| Tuesday, May 28, 2024 |
|
|
LEQEMBI (lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Ministry of Food and Drug Safety (MFDS) in South Korea has approved humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (lecanemab) for treatment in adult patients with mild cognitive impairment due to Alzheimer's disease (AD) or mild AD (early AD). more info >> |
|
| Thursday, May 23, 2024 |
|
|
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024 |
| Eisai Co., Ltd. announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO24), which is taking place virtually and in-person in Chicago, Illinois from May 31 to June 4. more info >> |
|
| Wednesday, May 22, 2024 |
|
|
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Launched In Japan |
| Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac group announced today that they have launched the anti-rheumatic agent "Metoject Subcutaneous Injection 7.5mg Pen 0.15mL, 10mg Pen 0.20mL, 12.5mg Pen 0.25mL and 15mg Pen 0.30mL" (methotrexate, "MTX"), in Japan. more info >> |
|
| Wednesday, May 15, 2024 |
|
|
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status |
| LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). more info >> |
|
| Monday, May 13, 2024 |
|
|
Eisai's Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures |
| Eisai Co., Ltd. announced today that it has received approval in China for the additional indication of its in-house discovered antiepileptic drug (AED) Fycompa (generic name: perampanel hydrate) for adjunctive treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older. more info >> |
|
| Thursday, April 18, 2024 |
|
|
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category) |
| Eisai Co., Ltd. announced today that "The Research on Treatments for Alzheimer's Disease Based on its Pathological Mechanisms" has received the Award for Science and Technology (Research Category) as a part of the FY2024 Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology. more info >> |
|
| Wednesday, April 17, 2024 |
|
|
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan |
| Eisai Co., Ltd. announced today that the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) for intravenous (IV) infusion has been launched in Japan. more info >> |
|
|
エーザイ、抗てんかん剤「フィコンパ(R)」の注射剤を新発売 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は本日、日本において自社創製の抗てんかん剤「フィコンパ(R)」（一般名：ペランパネル水和物、海外製品名：「Fycompa(R)」)の点滴静注用製剤について新発売したことをお知らせします。 more info >> |
|
| Wednesday, April 3, 2024 |
|
|
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics |
| Eisai Co., Ltd. announced today that its French sales subsidiary Eisai S.A.S. entered into an agreement to transfer the rights in France, the French Overseas Territories and Algeria (the "Territory") for the antipsychotic, "Loxapac" (generic name: loxapine) and the Parkinson's disease treatment "Parkinane LP" (generic name: trihexyphenidyl hydrochloride) to CNX Therapeutics Limited (Headquarters: London, UK, "CNX"). more info >> |
|
| Monday, April 1, 2024 |
|
|
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA |
| Eisai Co., Ltd. and Biogen Inc. announced today that Eisai submitted to the U.S. Food andDrug Administration (FDA) a Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI) intravenous (IV) maintenance dosing. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
2025年大阪・関西万博においてクィーンズランド州が 航空業界の脱炭素化に関する画期的な取組を発表
Aug 1, 2025 17:00: JST
|
|
|
2025 年大阪・関西万博でクィーンズランド州がグローバル教育を強力に推進
Aug 1, 2025 17:00: JST
|
|
|
Naoris Protocol Stakes $120,000 Bounty To Break Cryptography Securing $470 Trillion Global Economy
Aug 1, 2025 16:50 HKT/SGT
|
|
|
Queensland's Stralis lands clean aviation breakthrough in Japan, announced at Expo 2025 Osaka
Aug 1, 2025 17:00 JST
|
|
|
Queensland leads global education charge at Expo 2025 Osaka
Aug 1, 2025 17:00 JST
|
|
|
Honda Turkiye A.S. decided to establish Motorcycle Production Factory
Aug 1, 2025 16:45 JST
|
|
|
Global Property Expo | Singapore 2025 attracts 2,500 Buyers With Intent, 40+ Exhibitors, with Projects spanning 20 Countries
Aug 1, 2025 14:48 HKT/SGT
|
|
|
云天励飞拟赴港上市：中国AI推理芯片独角兽
Aug 1, 2025 14:35 HKT/SGT
|
|
|
国泰君安国际成功发行中资券商首笔公募数码原生债券
Aug 1, 2025 14:21 HKT/SGT
|
|
|
富士通、実用的な量子計算の実現に向けて、1万量子ビット超の超伝導量子コンピュータの研究開発を開始
Aug 1, 2025 10:30: JST
|
|
|
Honda Begins Joint Demonstration of Stationary Fuel Cell Power Station Designed to Utilize By-product Hydrogen and Repurposed Automotive Fuel Cells
Aug 1, 2025 11:20 JST
|
|
|
Isuzu's first battery-electric pickup "D-MAX EV" adopts eAxle
Aug 1, 2025 11:00 JST
|
|
|
A Bold New Chapter Begins at CEO SUITE
Aug 1, 2025 10:00 HKT/SGT
|
|
|
CEO SUITE開啟嶄新篇章
Aug 1, 2025 10:00 HKT/SGT
|
|
|
Shoucheng's Capital Leap: Zhao Tianyang Drives 2025 Upswing
Aug 1, 2025 09:40 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
